Boehringer Ingelheim and Click Therapeutics have shifted the dynamic of their long-term collaboration, which will see Click take the commercialisation reins for the pair’s digital therapeutic, CT-155.
Through this adjusted agreement, Boehringer will hand over $50m via a Series D financing round investment to help Click commercialise and market CT-155 – the pair’s co-developed prescription digital therapy designed to alleviate the negative symptoms experienced by adults with schizophrenia alongside standard of care (SoC) antipsychotic medication.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This will see Boehringer relinquish its post-marketing responsibilities for CT-155, which Jan Stefan Scheld, head of global therapeutic areas at Boehringer Ingelheim, noted will enable the continuation of CT-155’s co-development, while “leveraging Click’s capabilities and expertise to maximise its [CT-155’s] impact”.
The companies have been collaborating on this project since 2020, when the two inked a deal worth more than $500m to jointly progress the digital therapeutic through clinical trials to the commercial market. In the original pact, Boehringer and Click agreed to work together on developing the technology, while the former company would assume responsibility for its commercialisation and marketing.
The pair are eyeing approval for CT-155 based on the positive outcome of the Phase III CONVOKE study (NCT05838625), in which the digital therapeutic offered a 62% relative improvement in the prevalence and severity of negative schizophrenia symptoms experienced by patients alongside SoC antipsychotics.
To further explore the CT-155’s potential in improving schizophrenia outcomes, Boehringer will continue to lead the ENSPIRUS study (NCT06791122), which is looking at the impact of the app on symptoms and overall quality of life, as per an entry on ClinicalTrials.gov.
Digital health garners pharma clicks
CT-155 is one of seven regulated apps currently in development across several disease areas, as per GlobalData’s Medical Device Intelligence Center.
Analysts at GlobalData predict that regulatory-approved apps will rapidly grow in market value, with forecasts estimating strong, double-digit growth to 2034. Currently, North America and Europe are the largest markets for regulatory-approved apps globally.
However, this sector is still in the early stages of growth, and the landscape is highly competitive. This means that companies must find ways to successfully navigate evolving regulations and regional healthcare infrastructure to see success.
Wearables have also been garnering significant interest within the medtech industry lately, with a recent GlobalData report forecasting that the wearable tech industry will be worth $232.2bn by 2030.
In a previous interview with Medical Device Network, Click’s CEO, David Benshoof Klein, noted that wearables – another key area of growth within the digital health market – can no longer rely on collecting data and providing insights. Instead, these tools must be able to incorporate actionable insights to provide value to a user.
